Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15833659 | 0.89 | LIPG (0.35) | SMN1; SMN2HRH3NPC1CHRM3LIPG | |
| SCHEMBL22852605 | 0.84 | HRH3 (0.39) | SMN1; SMN2HRH3NPC1CHRM3KDM4E | |
| SCHEMBL17285631 | 0.83 | HRH3 (0.41) | SMN1; SMN2HRH3NPC1CHRM3HSD11B1 | |
| SCHEMBL22793895 | 0.80 | HRH3 (0.42) | SMN1; SMN2HRH3NPC1LIPGMEN1 | |
| SCHEMBL24661412 | 0.80 | SMN1; SMN2 (0.41) | SMN1; SMN2HRH3NPC1CHRM3HSD11B1 | |
| SCHEMBL3425518 | 0.79 | NPC1 (0.41) | SMN1; SMN2HRH3NPC1CHRM3LIPG | |
| SCHEMBL7903518 | 0.79 | HRH3 (0.43) | SMN1; SMN2HRH3NPC1CHRM3HSD11B1 | |
| SCHEMBL22852602 | 0.78 | NPC1 (0.42) | SMN1; SMN2HRH3NPC1HSD11B1KDM4E | |
| SCHEMBL23560002 | 0.77 | CARM1 (0.44) | HRH3 | |
| SCHEMBL23384465 | 0.76 | HRH3 (0.36) | SMN1; SMN2HRH3NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | SMN1; SMN2 1094/4885HRH3 1469/4885NPC1 4274/4885 |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | RET, BRAF, ROR1 | SMN1; SMN2 1115/4885HRH3 1487/4885NPC1 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.